Boston Scientific Corp. (NYSE:BSX)
The Company develops, manufactures & markets medical devices that are used in interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology & neuromodulation.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
hammerpants
(< 20)
Submitted: 4/12/2013 1:16:47 AM :
Start Price:
$7.68
BSX Score:
+14.05
Bsx has been the red headed stepchild for too long. Sure - interventional cardiology and crm isn't as glamorous as it once was, but there is still plenty of lettuce to be made. Business is finally leaner and out from under a lot of dead weight and regulatory trouble, still some improvements to go, but solid sales and distribution channels are there. A few technology breakthroughs or acquisitions away from blowing it away.
Recs
IfHeDiesHeDies
(43.73)
Submitted: 4/8/2013 7:23:52 PM :
Start Price:
$7.84
BSX Score:
+10.19
lOVE IT.
Recs
barryballs
(34.00)
Submitted: 1/7/2013 12:58:30 AM :
Start Price:
$5.95
BSX Score:
+39.14
Technicals
Recs
rondonovan
(< 20)
Submitted: 10/16/2012 3:10:21 PM :
Start Price:
$5.48
BSX Score:
+52.43
Fundamentally and compared to its peers BSX can be considered undervalued. A major player in two high barrier markets with demography on its side
Recs
aardvestor
(52.26)
Submitted: 8/28/2012 11:07:07 AM :
Start Price:
$5.47
BSX Score:
+49.04
BSX missed on revenue last quarter, but insiders believe things will turn around soon. CEO William Kucheman, President Michael Mahoney, and board member Ernest Mario have all bought shares recently.
Recs
akim088
(< 20)
Submitted: 7/27/2012 8:20:04 AM :
Start Price:
$5.02
BSX Score:
+60.12
coronary stents are still doing well. Market leader in less invasive procedures which I believe is the future of the medicine. Pipeline is still strong. JNJ still drooling over CRM side of BSX. Just waiting to ripe....
Recs
Recs
Recs
bradford86
(99.63)
Submitted: 1/10/2012 11:19:43 PM :
Start Price:
$5.53
BSX Score:
+35.78
255. Boston Scientific (NYSE: BSX) is bottoming. Target: $6-$7. Now is a good time to buy. I'll be voting on this with my caps points. Sure, it is cheap and it lacks catalysts. At this point, the catalyst is effectively a rhetorical question: "who is going to sell?" Since stock prices are a function of daily supply and demand, I expect that the lack of selling at these prices and the bottoming effect will drive the stock into my price range. Eventually, at prices low enough, investors kind of look around at each other and decide that selling doesn't make sense. At that point, you don't need catalysts for upside because you get a self-fulfilling bottoming prophecy that does it on its own.
http://beta.fool.com/bradford86/2012/01/10/price-market-part-37/
Recs
Danimal82
(< 20)
Submitted: 10/18/2011 4:17:18 PM :
Start Price:
$5.66
BSX Score:
+25.35
New stent coming Q411/Q112 (one in which 40% proceeds won't be going to Abbott), good pipeline/recent aquisitions, forward looking strategy, slowly but surely driving down debt, still a buyout possiblity (new president/CEO-to-be from JNJ..).
Recs
jnations92
(< 20)
Submitted: 7/8/2011 1:58:43 PM :
Start Price:
$7.15
BSX Score:
+3.57
Widespread hearing loss in the younger generations will boost sales of Boston Scientific's hearing aid division
Recs
Recs
pgraff101
(< 20)
Submitted: 2/18/2011 3:39:26 PM :
Start Price:
$7.51
BSX Score:
-2.28
Big money is all in on this one.
Recs
yanks129
(< 20)
Submitted: 2/18/2011 7:58:54 AM :
Start Price:
$7.40
BSX Score:
-0.32
doing the right things
Recs
HollowMountain
(< 20)
Submitted: 2/6/2011 11:17:13 AM :
Start Price:
$6.99
BSX Score:
+4.13
Important technology in an area of explosive growth and a huge budget for R&D. Debt could be a problem, but this company makes a huge amount of money and it appears that it could reach all of it's obligations if it came down to it.
Recs
nomo001
(< 20)
Submitted: 12/27/2010 9:03:53 PM :
Start Price:
$7.65
BSX Score:
-12.61
Under-appreciated stock on Wall Street. Strong Defibrillator and stent business.
Recs
hoperalot1
(< 20)
Submitted: 12/17/2010 3:26:24 PM :
Start Price:
$6.78
BSX Score:
-3.17
This one has been beaten down too long. Now transitioning to being a profitable, progressive company. Easily a 10 within 6 months
Recs
ardski
(< 20)
Submitted: 10/20/2010 1:59:18 PM :
Start Price:
$6.50
BSX Score:
-0.48
New line of products in future.
Recs
Burgermyster321
(46.74)
Submitted: 9/10/2010 5:47:53 PM :
Start Price:
$6.20
BSX Score:
-2.96
One of my biggest disappointments. I originally though this was a broken chart not a broken company it looks like I was wrong. Mid 8's seem reasonable
Recs
nogolf
(39.00)
Submitted: 7/26/2010 11:47:12 AM :
Start Price:
$5.98
BSX Score:
+3.50
New stent roll out marks significant campaign to regain market share and lost stature. 50% gain in 6 mos.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 201 : 1 2 3 4 5 6 7 8 9 10 Next »